Wolfgang Miesbach: First Lp(a)‑Specific Therapy in Secondary Prevention?
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, shared a post on LinkedIn about a recent article by Klaus G Parhofer et al, published in European Heart Journal, adding:
”First Lp(a)‑Specific Therapy in Secondary Prevention?
Pelacarsen Slashes Apheresis in Established CVD.
Elevated lipoprotein(a) [Lp(a)] is a frequent, genetically driven and largely lifestyle‑independent risk factor, present in approximately 20% of the general population and up to 25% of patients with ASCVD – yet we still have no approved Lp(a)‑lowering drug.
In the German Phase 3 Lp(a)FRONTIERS APHERESIS trial (51 patients with established CVD, isolated Lp(a) >60 mg/dL and a median of 44 LA sessions/year), pelacarsen 80 mg SC every 4 weeks almost abolished the need for weekly Lp(a) apheresis:
- normalized LA rate from 0.93 to 0.16 (≈99% reduction in odds of requiring LA),
- 69% complete LA avoidance from week 12–52 vs 0% on placebo,
- and ~72–77% sustained Lp(a) lowering, with mainly mild injection‑site reactions.
Huge congratulations to Dr Klaus Parhofer, Elisabeth Steinhagen-Thiessen and all co‑authors on these impressive data.
Pelacarsen may represent a major step toward a targeted, scalable therapy for genetically elevated Lp(a) in secondary prevention.”
Title: Pelacarsen and lipoprotein(a) apheresis in secondary prevention: the Lp(a)FRONTIERS APHERESIS trial
Authors: Klaus G. Parhofer, Ulrich Julius, Anna Laura Herzog, Thilo Krüger, Julia Weinmann-Menke, Gunnar H. Heine, Hui Cao, Jessica Schorr, Philippe Ferber, Jing Wang, Enrico Cristante, Björn Müller-Edenborn, Anja Vogt, Volker Schettler, Elisabeth Steinhagen-Thiessen
Stay updated on all scientific advances with Hemostasis Today.
-
Jun 7, 2026, 12:01Addressing Real-World Challenges in Thrombosis Care Through Case-Based Learning – Thrombosis Canada
-
Jun 7, 2026, 11:46Zehraan Ibni Akbar: Transforming Laboratory Data into Clinical Decisions Through Platelet Disorder Recognition
-
Jun 7, 2026, 11:31Alice Zerbinati: Y-90 Radioembolization Expands Curative Options for Advanced Hepatocellular Carcinoma
-
Jun 7, 2026, 09:26Filimon Dagnew Bezabih: SNMMI Honors 18F-GP1 PET Imaging for Innovation in Thrombosis Detection
-
Jun 7, 2026, 06:57Chandran Nadarajan: Targeted Endovascular Thrombolysis Offers Organ-Saving Benefits in Vascular Occlusions
-
Jun 7, 2026, 05:50Sayan Koley: Lupus Anticoagulant – A Key Marker in Thrombosis Risk Assessment
-
Jun 7, 2026, 05:45Nicolas Hubacz: Watching a Heart Build Its Network
-
Jun 7, 2026, 05:40New Evidence Highlights the Urgent Need for Gender-Inclusive Bleeding Disorders Research – EHC
-
Jun 7, 2026, 03:15Shirley D’Sa: What Comes After BTK Inhibitors in Waldenström Macroglobulinaemia?